Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti- CEA bispecific fusion proteins

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2909-2916

  Holliger, Philipp ^a   Manzke, Oliver ^b   Span, Mary ^b   Hawkins, Robert ^a   Fleischmann, Bernd ^b   Qinghua, Liu ^b   Wolf, Jürgen ^b   Diehl, Volker ^b   Cochet, Olivier ^c   Winter, Greg ^a   Bohlen, Heribert ^b,d  

^a MRC CENTRE FOR PROTEIN ENGINEERING   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c INSTITUT CURIE   (France)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; HYBRID PROTEIN;

ANTIGEN BINDING; ARTICLE; CARCINOMA CELL; CELL STIMULATION; COLON CARCINOMA; CYTOTOXICITY; DNA SEQUENCE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TARGET CELL;

AMINO ACID SEQUENCE; ANTIBODIES, BISPECIFIC; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD80; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DNA PRIMERS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0033564804     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Dwenger, A., Lindemann, A., and Mertelsmann, R. Minimal residual disease: detection, clinical relevance, and treatment strategies. J. Hematother., 5: 537-548, 1996.
2. Itoh, K., Platsoucas, C. D., and Balch, C. M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med., 168: 1419-1441, 1988.
3. Wong, J. T., Pinto, C. E., Gifford, J. D., Kurnick, J. T., and Kradin, R. L. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies. J. Immunol., 143: 3404-3411, 1989.
4. Becker, J. C., Brabletz, T., Czerny, C., Termeer, C., and Brocker, E. B. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int. Immunol., 5: 1501-1508, 1993.
5. Lee, P. P., Zeng, D., McCaulay, A. E., Chen, Y. F., Geiler, C., Umetsu, D. T., and Chao, N. J. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood, 90: 1611-1617, 1997.
6. Hermans, I. F., Daish, A., Yang, J., Ritchie, D. S., and Ronchese, F. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res., 58: 3909-3917, 1998.
7. Nitta, T., Sato, K., Yagita, H., Okumura, K., and Ishii, S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet., 335: 368-371, 1990.
8. Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Di Re, E. M., Eggermont, A. M., Goey, S. H., Gratama, J. W., Lamers, C. H., Nooy, M. A., Parmiani, G., Raspagliesi, F., Ravagnani, F., Scarfone, G., Trimbos, J. B., Warnaar, S. O., and Bolhuis, R. L. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst., 87: 1463-1469, 1995.
9. Kroesen, B. J., Buter, J., Sleijfer, D. T., Janssen, R. A., van der Graaf, W. T., The, T. H., De Leij, L., and Mulder, N. H. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer, 70: 652-661, 1994.
10. Bohlen, H., Manzke, O., Patel, B., Moldenhauer, G., Dorken, B., von Fliedner, V., Diehl, V., and Tesch, H. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res., 53: 4310-4314, 1993.
11. Mazzoni, A., Mezzanzanica, D., Jung, G., Wolf, H., Colnaghi, M. I., and Canevari, S. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res., 56: 5443-5449, 1996.
12. Jung, G., Ledbetter, J. A., and Muller-Eberhard, H. J. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc. Natl. Acad. Sci. USA, 84: 4611-4615, 1987.
13. Yokota, T., Milenic, D. E., Whitlow, M., and Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res., 52: 3402-3408, 1992.
14. Adams, G. P., Schier, R., McCall, A. M., Crawford, R. S., Wolf, E. J., Weiner, L. M., and Marks, J. D. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer, 77: 1405-1412, 1998.
15. Holliger, P., Brissinck, J., Williams, R. L., Thielemans, K., and Winter, G. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng., 9: 299-305, 1996.
16. Holliger, P., Prospero, T., and Winter, G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA, 90: 6444-6448, 1993.
17. Hochuli, E., Bannwarth, W., Dobeli, H., Gentz, R., and Stüber, D. Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate adsorbent. Biotechnology, 6: 1321-1325, 1988.
18. Munro, S., and Pelham, H. R. An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell, 46: 291-300, 1986.
19. Fitz Gerald, K., Holliger, P., and Winter, G. Improved tumor targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng., 10: 1221-1225, 1997.
20. Bohlen, H., Manzke, O., Engert, A., Hertel, M., Hippler-Altenburg, R., Diehl, V., and Tesch, H. Differentiation of cytotoxicity using target cells labeled with europium and samarium by electroporation. J. Immunol. Methods, 173: 55-62, 1994.
21. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260: 3440-3450, 1985.
22. Harwood, P. J., Britton, D. W., Southall, P. J., Boxer, G. M., Rawlins, G., and Rogers, G. T. Mapping epitope characteristics on carcinoembryonic antigen. Br. J. Cancer, 54: 75-82, 1986.
23. Zhu, Z., Zapata, G., Shalaby, R., Snedecor, B., Chen, H., and Carter, P. High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology (NY), 14: 192-196, 1996.
24. Helfrich, W., Kroesen, B. J., Roovers, R. C., Westers, L., Molema, G., Hoogenboom, H. R., and de Leij, L. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int. J. Cancer, 76: 232-239, 1998.
25. Mulcahy, H. E., Patchett, S. E., Daly, L., and O'Donoghue, D. P. Prognosis of elderly patients with large bowel cancer. Br. J. Surg., 81: 736-738, 1994.
26. Riethmuller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Bruggish, P., Witte, J., and the German Cancer Aid 17-1A Study Group. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet, 343: 1177-1183, 1994.
27. Lanzaveccia, A., and Scheidegger, D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol., 17: 105-111, 1987.
28. Demanet, C., Brissinck, J., Van, M. M., Leo, O., and Thielemans, K. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J. Immunol., 147: 1091-1097, 1991.
29. Weiner, G. J., and Hillstrom, J. R. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immunol., 147: 4035-4044, 1991.
30. Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V., Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., Mrozek-Orlowski, M., Wardwell, K., Guyre, V., Morley, T. L., Aroizu, C., and Fonger, M. W. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol., 13: 2281-2292, 1995.
31. Hartmann, F., Renner, C., Jung, W., Sahin, U., and Pfreundschuh, M. Treatment of Hodgkin's disease with bispecific antibodies. Ann. Oncol., 4: 143-146, 1996.
32. Manzke, O., Titzer, S., Tesch, H., Diehl, V., and Bohlen, H. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma. Cancer Immunol. Immunother., 45: 198-202, 1997.
33. Hayden, M. S., Grosmaire, L. S., Norris, N. A., Gilliland, L. K., Winberg, G., Tritschler, D., Tsu, T. T., Linsley, P. S., Mittler, R. S., Senter, P. D., Fell, H. P., and Ledbetter, J. A. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Antigens, 48: p242-54, 1996.
34. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
35. Gerstmayer, B., Altenschmidt, U., Hoffmann, M., and Wels, W. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J. Immunol., 158: 4584-4590, 1997.
36. Chester, K. A., Begent, R. H. J., Robson, L., Keep, P., Pedley, R. B., Boden, J. A., Boxer, G., Green, A., Winter, G., Cochet, O., and Hawkins, R. E. Phage libraries for generation of clinically useful antibodies. Lancet, 343: 455-456, 1994.